March 丨 Shenzhen Chipscreen Biosciences Co., Ltd. was established

Successfully constructed an internationally advanced integrated drug discovery and early evaluation platform based on chemical genomics.

The peroxisome proliferator-activated receptor pan-agonist Chiglitazar Sodium was discovered for the first time.

The subtype-selective histone deacetylase inhibitor Chidamide was discovered for the first time.

December 丨 Signed a cross-licensing agreement with the National Center for Toxicological Research (NCTR),

a branch of the U.S. FDA, to develop software for toxicogenomics applications.

Submitted a clinical trial application for the original diabetes treatment drug Chiglitazar Sodium to the China

National Medical Products Administration.

June丨The Phase I clinical trial of Chiglitazar Sodium was formally approved by the China National Medical Products Administration.

December丨Submitted a clinical trial application for the original anti-tumor drug Chidamide to the China National Medical Products Administration.

December丨Chipscreen Biosciences' "Innovative Chemical Drug Engineering Technology Center" was recognized as a municipal-level engineering center.

October丨Out-licensed the patent and commercialization rightsof Chidamide in the United States, European Union, Japan,

and other countries to HUYABIO International of the United States.

November丨The Phase I clinical trial of Chidamide was formally approved by the China National Medical Products Administration.

November丨Completed the Phase IIa clinical trial of Chiglitazar Sodium, achieving the objective of proof-of-concept for treatment.

The multi-target selective kinase inhibitor Chiauranib was discovered for the first time.

May 丨 Completed the Phase I clinical trial of Chidamide in China, demonstrating encouraging efficacy and safety.

March丨Chidamide entered clinical trials for rare oncology indications with the purpose of marketing approval.

June丨Chipscreen Biosciences was selected as one of the first "Enterprise Innovative Drug Incubation Bases" under the National Major Scientific and Technological Project of "Significant New Drug Development".

July丨The Shenzhen Municipal Government launched the "Shenzhen Biomedical Accelerator Pilot Project" tailored for the industrialization of Chidamide.

January丨The Phase I clinical trial of Chidamide was approved by the U.S. FDA.

July丨Applications for Phase II and III clinical trials of Chidamide for the treatment of solid tumors including non-small cell lung cancer, breast cancer, and prostate cancer were approved by the China National Medical Products Administration.

March丨The application for the registrational Phase III clinical trial of Chiglitazar Sodium was approved by the China National Medical Products Administration.

August丨Submitted a clinical trial application for Chiauranib for the treatment of tumors to the China National Medical Products Administration.

February丨Completed the Phase II clinical trial of Chidamide and submitted expedited New Drug Certificate and marketing authorization application for the indication of PTCL to the China National Medical Products Administration.

August丨The Phase I clinical trial application for Chiauranib was approved by the China National Medical Products Administration.

October丨Licensed the patent rights for Chidamide in Chinese Taiwan to GNT Biotech & Medicals Corporation.

The selective JAK3/JAK1/TBK1 kinase inhibitor CS12192 was discovered for the first time.

April丨Established the wholly owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd.

July丨The Phase I clinical trial of Chidamide was approved by the Japanese PMDA.

December 丨 Chidamide was approved for marketing by the China National Medical Products Administration.

• The world's first subtype-selective histone deacetylase (HDAC) inhibitor.
• The world's first oral drug for the treatment of PTCL, filling a gap in the therapeutic field of peripheral T-cell lymphoma.
• China's first original rare disease new drug (National Class 1.1) approved for marketing based on Phase II clinical trial results.

February丨Chidamide production base passed GMP certification, and the product was launched for marketing.

July丨Initiated a Phase III clinical trial of Chidamide combined with Exemestane for the treatment of hormone receptor-positive advanced breast cancer.

April丨The application for a Phase III clinical trial of Chidamide for the treatment of breast cancer was approved by the Chinese Taiwan TFDA.July丨Chidamide was included in the National Medical Insurance Drug List.

October丨The construction of Chengdu Chipscreen Pharmaceutical's innovative drug R&D center and regional headquarters project officially commenced.

March丨The application for Phase II/III clinical trials of Chiauranib was approved by the China National Medical Products Administration.

May丨Completed the Phase III clinical trial of Chidamide for the treatment of breast cancer in China.

June丨Submitted a marketing application to the China National Medical Products Administration for the breast cancer indication of Chidamide.

November丨Chipscreen Biosciences' “Chemical Innovative Drug Engineering Technology Research Center” was rated as a provincial-level engineering technology research center.

August 12, listed on the Science and Technology Innovation Board.

September 丨 The new drug application for Chiglitazar Sodium in the treatment of type 2 diabetes was accepted by the China National Medical Products Administration.

November 丨 The marketing application for Chidamide in the treatment of breast cancer was approved by the China National Medical Products Administration.

October丨The new drug application for Chidamide in the treatment of adult T-cell leukemia was accepted by the Japanese Pharmaceuticals and Medical Devices Agency, marking the first new drug application for an indication of Chidamide submitted in Japan.

October丨Completed the registration of the wholly-owned U.S. subsidiary, Chipscreen Biosciences (United States) Limited.

March丨The indication of Chiauranib for the treatment of ovarian cancer was included in the “Breakthrough Therapy Designation” by the Center for Drug Evaluation of the China National Medical Products Administration; the application for the pivotal Phase III clinical trial was approved by the China National Medical Products Administration.

April丨The application for Phase Ib/II clinical trials of Chiauranib in the treatment of advanced solid tumors was approved by the U.S. FDA, marking the first clinical trial application for an indication of Chiauranib submitted in the United States.

June丨The marketing application for Chidamide in the treatment of adult T-cell leukemia was approved by the Japanese Pharmaceuticals and Medical Devices Agency, making it the first Chinese-originated innovative drug approved for marketing overseas.

October丨The marketing application for Chiglitazar Sodium in the treatment of type 2 diabetes was approved for marketing by the China National Medical Products Administration.

December丨The indication of Chidamide monotherapy for the treatment of relapsed or refractory peripheral T-cell lymphoma was approved for marketing in Japan.

April丨The Group's new headquarters and R&D center were officially put into use.

November丨Chengdu Chipscreen Pharmaceutical was certified as a national high-tech enterprise.

January丨The original innovative drug Chiglitazar Sodium for the treatment of type 2 diabetes was included in the National Medical Insurance Drug List for the first time.

March丨Chipscreen Biosciences' original innovative drug Chidamide was approved for the breast cancer indication in Chinese Taiwan.

June丨The application for Phase I clinical trials of CS23546, a new oral small-molecule anti-tumor immunotherapy drug, was approved by the China National Medical Products Administration.

October丨The clinical trial application for CS32582 capsules, a novel immunomodulatory small molecule drug for the treatment of psoriasis, was approved by the National Medical Products Administration.

February丨The phase II clinical trial of Chiglitazar Sodium monotherapy for nonalcoholic steatohepatitis achieved its primary efficacy endpoint.

April丨The indication of Chidamide in combination with R-CHOP for the treatment of diffuse large B-cell lymphoma was approved.

June丨The indication of Chidamide in combination with sintilimab and bevacizumab for advanced colorectal cancer was included in the “Breakthrough Therapy Designation”.

June丨The application for a phase II clinical trial of Chiauranib combined with albumin-bound paclitaxel and gemcitabine as first-line treatment for advanced pancreatic cancer was approved.

July丨The marketing application for Chiglitazar Sodium in combination with metformin for the treatment of type 2 diabetes was officially approved.

July丨The application for a phase III clinical trial of Chidamide in combination with sintilimab and bevacizumab for the treatment of colorectal cancer was approved.

December丨The clinical trial application for CS231295 tablets, a brain-penetrant selective Aurora B inhibitor, was approved by the National Medical Products Administration.

December丨The new DLBCL indication of Chidamide was successfully included in the National Medical Insurance Drug List, and Chiglitazar Sodium (for type 2 diabetes indication) was successfully renewed in the List at the original price.

January丨The clinical trial application for CS12088 tablets, a novel anti-hepatitis B virus drug, was approved by the National Medical Products Administration.

February丨The application for a phase III clinical trial of Chidamide tablets in combination with CHOP for the treatment of previously untreated peripheral T-cell lymphoma with T follicular helper phenotype was approved.